Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 91, Issue 1, Pages 50-58
Publisher
Wiley
Online
2015-10-23
DOI
10.1002/ajh.24221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
- (2015) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
- (2015) J. D. Milosevic Feenstra et al. BLOOD
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Mutation Order on Myeloproliferative Neoplasms
- (2015) Christina A. Ortmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
- (2015) T Barbui et al. Blood Cancer Journal
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Myeloproliferative Neoplasms
- (2015) Ayalew Tefferi et al. JAMA Oncology
- Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management
- (2014) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Discriminating between essential thrombocythemia and masked polycythemia vera inJAK2mutated patients
- (2014) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
- (2014) Alberto Alvarez-Larrán et al. ANNALS OF HEMATOLOGY
- Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms
- (2014) E. Chen et al. BLOOD
- The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
- (2014) A. Tefferi et al. BLOOD
- Presence of calreticulin mutations in JAK2-negative polycythemia vera
- (2014) J. Broseus et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
- (2014) T. Barbui et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
- (2014) Ramy A. Abdelrahman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
- (2014) A Pardanani et al. LEUKEMIA
- Calreticulin mutations and long-term survival in essential thrombocythemia
- (2014) A Tefferi et al. LEUKEMIA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib
- (2014) R A Abdelrahman et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
- (2014) A Tefferi et al. LEUKEMIA
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
- (2014) A Tefferi et al. LEUKEMIA
- Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
- (2014) Bruno Cassinat et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience
- (2013) Ann Brinch Madelung et al. AMERICAN JOURNAL OF HEMATOLOGY
- Masked polycythemia Vera (mPV): Results of an international study
- (2013) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Masked polycythemia vera diagnosed according to WHO and BCSH classification
- (2013) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype
- (2013) A Tefferi et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms
- (2012) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis
- (2011) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-term outcome of pomalidomide therapy in myelofibrosis
- (2011) Kebede H. Begna et al. AMERICAN JOURNAL OF HEMATOLOGY
- Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
- (2011) R. Vaidya et al. BLOOD
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia
- (2011) Jean-Guillaume Dillinger et al. THROMBOSIS RESEARCH
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
- (2009) K. Hussein et al. BLOOD
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
- (2009) Mrinal M. Patnaik et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
- (2009) A Tefferi et al. LEUKEMIA
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started